Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 483
Posts 81,357
Boards Moderated 20
Alias Born 09/05/02
160x600 placeholder
IBM posted sharply lower earnings in its third quarter as sales fell across most of its segments and it unveiled a deal to transfer its semiconductor operations to Globalfoundries. IBM shares down 7% premarket.
More Top Equities Stories Of The Day
U.S. Stocks Mixed as IBM Drags Dow Down
FTSE 100 Loses Ground In Topsy-turvy Trade; Shire Losses Deepen
Stifel Financial to Hire Two Former Merrill Lynch Advisers
U.S. Stocks Gain, but IBM Weighs on Dow
U.S. Stocks Rebound After Recent Losses
U.S. Hot Stocks: Hot Stocks to Watch
India's Snapdeal in Talks With SoftBank, Others
Halliburton Guidance Expected to Shed Light On Oil Price Worries -- Earnings Preview
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 183004 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist